PT-141 / Caffeine – Rapid Dissolve Mini-Tabs

Available Dosage Strengths

2 mg / 50 mg

Want to Prescribe?

Disclaimer: Images are for reference only; actual products may vary.

Product Overview

PT-141 (Bremelanotide) is a peptide therapy that may enhance sexual arousal and libido by activating melanocortin receptors in the brain. The PT-141/caffeine rapid dissolve tablet combines the pro-libido effects of PT-141 with the energizing benefits of caffeine, offering fast-acting support for sexual vitality. Designed for sublingual or buccal use, this formulation ensures convenient, rapid absorption.

Bremelanotide (PT-141) 1,2

Bremelanotide (PT-141) is a melanocortin receptor (MCR) agonist. It is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:

  • A co-existing medical or psychiatric condition,
  • Problems with the relationship, or the effects of medication or drug substance

Caffeine3-6

Caffeine, structurally a xanthine, is a central nervous system and respiratory stimulant. It has vasodilatory effects on the vasculature. It has been shown to increase mental alertness and arousal, aid in resolution of a headache through its effect on the vasculature and it facilitates respiratory function in neonates with apnea.3-5 In addition, there has been some research on its effects to increase genital blood flow.6

Bremelanotide (PT-141) 1,2

Bremelanotide, a MCR agonist, non-selectively works on several receptor subtypes MC1R-MC5R in the central nervous system. MC1R and MC4R are thought to be the most relevant. MC4R are commonly present in the central nervous system. This drug is thought to work by activating pathways in the brain that are involved in sexual responses.

Caffeine

Caffeine is an adenosine-receptor antagonist that promotes inotropic effects in the heart and release of catecholamines to facilitate stimulatory effects. In the vasculature, caffeine promotes vasodilation through its ability to antagonize adenosine and stimulate endothelial cells to release nitric oxide. Through caffeine inhibition of adenosine receptors, the drug increases central respiratory drive and stimulates respiratory drive through its ability to increase pulmonary response to carbon dioxide in the medullary system.

Bremelanotide (PT-141)1,2  

Common

  • Gastrointestinal including nausea and vomiting
  • Increased blood pressure
  • Hyperpigmentation

 

Caffeine3,4

Common

  • Anxiety
  • Restlessness
  • Insomnia
  • Tremors
  • Increased heart rate

Bremelanotide (PT-141)1,2

Contraindications:

  • Known hypersensitivity to bremelanotide or any component of the formulation
  • Patients with uncontrolled hypertension and cardiovascular disease
  • Pregnancy not recommended when taking bremelanotide

Precautions:

  • Use caution in patients with renal or hepatic impairment

Caffeine3,4

Contraindications

  • Known hypersensitivity to caffeine

Precautions

  • Severe anxiety
  • Cardiovascular disease
  • Peptic ulcer disease
  • Hepatic or renal impairment

Store in a cool, dry place, away from direct light and heat; Room temperature (20°C–25°C / 68°F–77°F) is ideal. Keep out of reach of children and pets.

  1. Bremelanotide package insert. www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf 
  2. Clinical Pharmacology bremelanotide clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  3. Clinical Pharmacology caffeine clinical monograph 2025 https://www.clinicalkey.com/pharmacology/
  4. Evans J, Richards JR, Battisi A. Caffeine StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK519490/. May 29, 2024. Accessed July 15, 2025
  5. Caffeine for the Sustainment of Mental Task Performance: Formulations for Military Operations (Pharmacology of Caffeine) 2001 https://www.ncbi.nlm.nih.gov/books/NBK223808/. Access July 15, 2025
  6. Karimi M, Asbaghi O, Kazemi K, Sedgi FM, Soleimani E, Moghadam HK. Association between caffeine intake and erectile dysfunction: a meta-analysis of cohort studies. J Health Popul Nutr. 2024 Sep 28;43(1):154.

This information is for educational purposes only. This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness. This product is not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding treatment, cure, or prevention of any disease or condition.

This information may not cover all possible drug information about this product. Call your doctor for medical advice and/or about side effects. You may report side effects to the FDA at 1-800-FDA-1088.  A Wells Pharmacy Network pharmacist will be happy to answer any questions. For consultation, please call 1-800-622-4510.

EXPLORE MORE

Related Medications

We deliver your orders fast and with complete discretion, straight to your door.

We're licensed to ship nationwide

Our mission is to elevate compounding industry standards through a unique combination of superior science and service.

Ready to get started?